EI

259.5

-1.48%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

FRE

46.44

+0.3%↑

EI

259.5

-1.48%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

FRE

46.44

+0.3%↑

EI

259.5

-1.48%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

FRE

46.44

+0.3%↑

EI

259.5

-1.48%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

FRE

46.44

+0.3%↑

EI

259.5

-1.48%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

FRE

46.44

+0.3%↑

Search

Sanofi SA

Suletud

SektorTervishoid

84.4 -1.16

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

84.37

Max

85.01

Põhinäitajad

By Trading Economics

Sissetulek

1.1B

2.9B

Müük

129M

11B

P/E

Sektori keskmine

16.75

35.724

Aktsiakasum

1.59

Dividenditootlus

4.49

Kasumimarginaal

27.303

Töötajad

82,878

EBITDA

-881M

1.9B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+24.23% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.49%

3.09%

Järgmine tulemuste avaldamine

24. okt 2025

Turustatistika

By TradingEconomics

Turukapital

1.2B

105B

Eelmine avamishind

85.56

Eelmine sulgemishind

84.4

Uudiste sentiment

By Acuity

33%

67%

97 / 372 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Sanofi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2025, 10:06 UTC

Suurimad hinnamuutused turgudel

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31. juuli 2025, 06:00 UTC

Tulu

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

30. juuli 2025, 10:20 UTC

Tulu

Santander Reports Higher Profit, but Regional Picture is Mixed -- Update

30. juuli 2025, 05:31 UTC

Tulu

Santander Sticks to Guidance, Launches $2 Billion Buyback After Profit Rises

28. aug 2025, 09:00 UTC

Market Talk

Santander Could Deliver Even Higher Returns -- Market Talk

6. aug 2025, 05:02 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Completes the Acquisition of Vigil Neuroscience

6. aug 2025, 05:00 UTC

Omandamised, ülevõtmised, äriostud

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1. aug 2025, 13:16 UTC

Tulu

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1. aug 2025, 12:40 UTC

Tulu

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31. juuli 2025, 08:15 UTC

Market Talk
Tulu

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31. juuli 2025, 05:56 UTC

Market Talk
Tulu

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31. juuli 2025, 05:30 UTC

Tulu

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31. juuli 2025, 05:30 UTC

Tulu

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31. juuli 2025, 05:30 UTC

Tulu

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31. juuli 2025, 05:30 UTC

Tulu

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31. juuli 2025, 05:30 UTC

Tulu

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31. juuli 2025, 05:30 UTC

Tulu

Sanofi 2Q Business Operating Profit EUR2.46B

31. juuli 2025, 05:30 UTC

Tulu

Sanofi 2Q Adj EPS EUR1.59

31. juuli 2025, 05:30 UTC

Tulu

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

31. juuli 2025, 05:30 UTC

Tulu

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

31. juuli 2025, 05:30 UTC

Tulu

Sanofi 2Q Net Pft EUR3.94B

31. juuli 2025, 05:30 UTC

Tulu

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

31. juuli 2025, 05:30 UTC

Tulu

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

31. juuli 2025, 05:30 UTC

Tulu

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

31. juuli 2025, 05:30 UTC

Tulu

Sanofi 2Q Sales EUR9.99B

31. juuli 2025, 05:30 UTC

Tulu

Sanofi Backs 2025 EPS Adj View

31. juuli 2025, 05:30 UTC

Tulu

Sanofi Narrows 2025 Sales View

31. juuli 2025, 05:30 UTC

Tulu

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

30. juuli 2025, 07:48 UTC

Market Talk
Tulu

Santander Results Get Lukewarm Reaction -- Market Talk

30. juuli 2025, 06:41 UTC

Market Talk
Tulu

Santander's Strategic Investments in Focus -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Sanofi SA Prognoos

Hinnasiht

By TipRanks

24.23% tõus

12 kuu keskmine prognoos

Keskmine 106.039 EUR  24.23%

Kõrge 124 EUR

Madal 81.476 EUR

Põhineb 14 Wall Streeti analüütiku instrumendi Sanofi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

14 ratings

10

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

91.3 / 96.1Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

97 / 372 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.